|
A Biomarker Study on Tumour Tissue in Patients with NSCLC |
A Biomarker Study on Tumour Tissue in Patients with NSCLC |
Dr Gary Doherty |
28 Feb 2021 |
29 Jun 2020 |
Lung |
|
ABC-07 |
Addition of stereotactic radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers |
Dr Thankamma Ajithkumar |
31 Aug 2023 |
5 Apr 2017 |
Liver & Bile Duct |
|
Add-Aspirin Trial |
A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours |
Dr Luke Hughes-Davies |
11 Dec 2020 |
21 Dec 2015 |
Breast, Colorectal, Oesophageal, Prostate |
|
ADSCaN |
A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer |
Dr David Gilligan |
31 Dec 2021 |
23 Nov 2017 |
Lung |
|
ALF Research Study |
Research into Altered Lymphocyte Function in Health and Disease |
Dr Kate Fife |
31 Dec 2022 |
9 Nov 2017 |
Skin & melanoma |
|
ALL-RIC |
A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission |
Dr Ben Uttenthal |
30 Sep 2020 |
15 Mar 2019 |
Haematological |
|
Amadeus |
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation |
Dr Charles Crawley |
31 Dec 2022 |
19 Dec 2019 |
Haematological |
|
AML 18 |
A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome |
Dr Kiran Tawana |
31 Dec 2020 |
7 Dec 2015 |
Haematological |
|
Ariel 4 (CANC 5651) |
A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Dr James Brenton |
30 Dec 2020 |
11 Apr 2017 |
Gynaecological |
|
ATOMIC-Meso |
Randomized, Double-Blind Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin |
Dr David Gilligan |
30 Dec 2020 |
5 Mar 2018 |
Lung |
|
BEAT-meso |
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma |
Dr David Gilligan |
15 Jan 2025 |
5 Sep 2019 |
Lung |
|
BRITER |
Brain Imaging to predict Toxicity in Elderly patients after Radiotherapy |
Dr Gary Doherty |
31 Mar 2021 |
10 Jan 2019 |
Brain and CNS |
|
Canopy-A |
Adjuvant canakinumab vs placebo in stages II-IIIB resected NSCLC |
Dr Gary Doherty |
30 Jun 2021 |
17 Apr 2019 |
Lung |
|
Cervical Cell Lift |
Collection of Cervical Cells at Colposcopy using a novel technique for analysis of high risk vs. low risk lesions |
Dr Robin Crawford |
31 Dec 2020 |
14 Jul 2017 |
Gynaecological |
|
CHIRON |
An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer |
Dr Gary Doherty |
31 Oct 2021 |
21 Jan 2020 |
Lung |
|
CompARE Trial |
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer |
Dr Rashmi Jadon |
31 Jan 2026 |
5 Mar 2019 |
Head & neck |
|
COSMIC-313 |
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk |
Dr Kate Fife |
31 Dec 2025 |
6 Dec 2019 |
Kidney |
|
Dante |
A randomised phase III trial to evaluate the duration of anti-PD1 monoclonal antibody treatment in patients with metastatic melanoma |
Dr Pippa Corrie |
31 Mar 2023 |
21 Sep 2018 |
Skin & melanoma |
|
DIG (Diffusion imaging in gliomas) |
Quantitative diffusion imaging for early treatment response and progression evaluation in adult high grade gliomas; a multicentre study |
Dr Tomasz Matys |
31 Dec 2022 |
13 Jul 2018 |
Brain and CNS |
|
DS8201-A-U205 (Daiichi) |
A phase 2, open-label, single-arm trial of Trastuzumab Deruxtecan (DS-8201A) in HER2-positive, unresectable ormetastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a Trastuzumab containing regime |
Dr Lizzie Smyth |
1 Apr 2022 |
13 Dec 2019 |
Oesophageal |
|
EMBRACE-II |
Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer |
Dr Li Tee Tan |
30 Jun 2024 |
7 Nov 2017 |
Gynaecological |
|
EMT2 |
A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases |
Dr Lizzie Smyth |
31 Jul 2021 |
30 Oct 2019 |
Colorectal |
|
ENRICH Ibrutinib for untreated mantle cell lymphoma |
Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma |
Dr George Follows |
31 Mar 2022 |
14 May 2020 |
Haematological |
|
EuroNet-PHL-C2 |
Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents |
Dr Ben Uttenthal |
30 Sep 2021 |
30 Oct 2018 |
Haematological |
|
FIGHT 302 |
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement |
Dr Bristi Basu |
18 Oct 2021 |
4 Jul 2019 |
Liver & Bile Duct |
|
FOCUS 4 |
FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme |
Dr Hugo Ford |
25 Nov 2020 |
1 Dec 2015 |
Colorectal |
|
Hamlet.rt (H&N) |
Hamlet.rt - Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy |
Dr Raj Jena |
31 Oct 2021 |
24 Oct 2019 |
Head & neck |
|
Hamlet.rt (Prostate) |
Hamlet.rt - Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy |
Dr Raj Jena |
31 Oct 2021 |
24 Oct 2019 |
Prostate |
|
ICI Genetics |
Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity’ |
Dr Gary Doherty |
14 Feb 2021 |
12 Apr 2019 |
Lung |
|
ICONIC |
Improving outcomes through collaboration in osteosarcoma |
Dr Han Wong |
30 Sep 2022 |
13 Dec 2019 |
Sarcoma |
|
KEYLYNK-010 |
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next generation Hormonal Agent (NHA) and Chemotherapy |
Dr Danish Mazhar |
30 Dec 2020 |
24 Sep 2019 |
Prostate |
|
Keynote 937 |
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation |
Dr Bristi Basu |
30 Jun 2021 |
2 Aug 2019 |
Liver & Bile Duct |
|
KEYNOTE-641 |
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Dr Danish Mazhar |
30 Apr 2024 |
8 Oct 2019 |
Prostate |
|
KEYNOTE-921 |
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) |
Dr Danish Mazhar |
30 Dec 2020 |
24 Sep 2019 |
Prostate |
|
Mediola |
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors |
Dr Christine Parkinson |
18 Oct 2020 |
18 Oct 2018 |
Gynaecological |
|
MelResist |
Investigating resistance to gene-targeted melanoma therapies |
Dr Pippa Corrie |
31 Dec 2021 |
3 Dec 2011 |
Skin & melanoma |
|
Minitub Registration Study (EORTC 1208) |
Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissection (CLND) or Nodal Observation |
Dr Amer Durrani |
1 May 2021 |
19 Oct 2017 |
Skin & melanoma |
|
MITRE |
Microbiome Immunotherapy Toxicity and Response Evaluation (MITRE) An observational study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy |
Dr Pippa Corrie |
31 Dec 2024 |
30 Mar 2021 |
Kidney |
|
MyeChild 01 |
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy |
Dr Michael Gattens |
1 Nov 2021 |
31 Oct 2016 |
Haematological |
|
Myeloma XII |
A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem |
Dr Charles Crawley |
31 Dec 2021 |
22 May 2017 |
Haematological |
|
National Lung Matrix Trial |
Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer |
Dr David Gilligan |
31 Dec 2020 |
17 Nov 2015 |
Lung |
|
OPTIMA |
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis |
Dr Luke Hughes-Davies |
31 Oct 2020 |
25 Oct 2012 |
Breast |
|
PACE-C |
International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for organ-confined prostate cancer |
Dr Alex Martin |
26 Apr 2026 |
5 Feb 2020 |
Prostate |
|
PARTNER |
Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA |
Dr Jean Abraham |
31 Mar 2021 |
12 May 2016 |
Breast |
|
PATHOS |
A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer |
Dr Ekpemi Irune |
31 Dec 2021 |
16 Jun 2017 |
Head & neck |
|
PEACE |
The PEACE (Posthumous tissuE donAtion in CancEr) Study |
Dr James Brenton |
8 Oct 2020 |
8 Oct 2018 |
Gynaecological, Breast |
|
Pharmacyclics PCYC 1141 (Bruton's Tyrosine Kinase Inhibitor, Treatment for Follicular Lymphoma) |
A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma |
Dr George Follows |
16 Mar 2025 |
27 Jul 2018 |
Haematological |
|
Pioneer |
Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer |
Dr Richard Baird |
31 Dec 2020 |
20 Jul 2017 |
Breast |
|
plasmaMATCH |
A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (Only cohort for Triple Negative Breast Cancer remains open) |
Dr Richard Baird |
31 Dec 2020 |
11 Apr 2017 |
Breast |
|
PLATO |
PersonaLising Anal cancer radioTherapy dOse |
Dr Catherine Jephcott |
31 Dec 2022 |
22 Mar 2017 |
Colorectal |
|
POPS |
A randomised phase II trial assessing Post-Operative use of ProSpare, a rectal obturator in prostate cancer radiotherapy |
Dr Yvonne Rimmer |
31 Dec 2021 |
4 Jul 2017 |
Prostate |
|
PORTICOtrans |
PORTICOtrans: A feasibility study to evaluate the immune-milieu in patients undergoing Whipple’s resection, comparing the utility of trans-duodenal biopsy, frozen and FFPE resection specimens |
Dr Duncan Jodrell |
26 Jun 2021 |
10 Oct 2019 |
Pancreatic |
|
PRaM-GBM |
Predicting sites of tumour progression in the invasive margin of glioblastomas |
Mr Stephen Price |
31 Dec 2020 |
1 Feb 2017 |
Brain and CNS |
|
PRECISION-Panc |
Advancing personalised medicine treatment strategies for pancreatic cancer |
Dr Bristi Basu |
28 Feb 2023 |
25 Apr 2018 |
Pancreatic |
|
PRIMETIME |
Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers |
Dr Charlotte Coles |
31 Dec 2021 |
18 May 2017 |
Breast |
|
PRIMUS-001 |
An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation |
Dr Pippa Corrie |
30 Apr 2022 |
10 May 2018 |
Pancreatic |
|
Quality of Life After Bladder Cancer (Q-ABC) |
A comparison of patient related outcomes following radical surgery and radiotherapy |
Dr Yvonne Rimmer |
1 Mar 2022 |
23 Oct 2018 |
Bladder |
|
RAIDER |
A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder |
Dr Yvonne Rimmer |
31 Mar 2029 |
6 Jan 2016 |
Bladder |
|
RAMPART |
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse |
Dr Sarah Welsh |
31 Dec 2023 |
20 Jul 2018 |
Kidney |
|
rEECur |
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma |
Dr Han Wong |
30 Sep 2022 |
5 May 2016 |
Sarcoma |
|
ROAM |
Radiation versus observation following surgical resection of atypical meningioma: A randomised controlled trial |
Dr Sarah Jefferies |
30 Apr 2025 |
17 Nov 2016 |
Brain and CNS |
|
SARON |
Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial |
Dr Alex Martin |
4 Jul 2023 |
9 Aug 2017 |
Lung |
|
SPECTA (EORTC 1553) |
Screening cancer patients for efficient clinical trial access |
Dr Sarah Welsh |
31 Dec 2021 |
1 Aug 2018 |
Kidney |
|
SPECTA (EORTC 1553) (Sarcoma) |
Screening cancer patients for efficient clinical trial access |
Dr Helen Hatcher |
31 Dec 2021 |
1 Aug 2018 |
Sarcoma |
|
SPECTA (EORTC 1553) (Skin & Melanoma) |
Screening cancer patients for efficient clinical trial access |
Dr Kate Fife |
31 Dec 2021 |
1 Aug 2018 |
Skin & melanoma |
|
SPRING |
Seizure prophylaxis in Glioma |
Mr Stephen Price |
31 May 2023 |
11 Dec 2019 |
Brain and CNS |
|
SSGXXII |
Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study |
Dr Ramesh Bulusu |
31 Dec 2020 |
1 Mar 2017 |
Sarcoma |
|
Target Fal01 |
Translational Analysis and Research in Gynaecological Epithelial Tissues - Fallopian Tubes |
Dr Filipe Correia Martins |
30 Nov 2021 |
11 Jan 2019 |
Gynaecological |
|
Topaz |
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers |
Dr Pippa Corrie |
20 Nov 2020 |
18 Jun 2019 |
Liver & Bile Duct |
|
UK P3BEP Trial |
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
Dr Danish Mazhar |
30 Dec 2020 |
5 May 2017 |
Testicular |
|
UTX-TGR-205 (Unity NHL) |
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma. (Only open to Follicular and Marginal Zone Lymphomas) |
Dr Dan Hodson |
29 Dec 2020 |
29 Dec 2017 |
Haematological |
